Serum Thyroid Hormone Antibodies Are Frequent in Patients with Polyglandular Autoimmune Syndrome Type 3, Particularly in Those Who Require Thyroxine Treatment

Roberto Vita1*, Maria Giulia Santaguida2, Camilla Virili2, Maria Segni3, Marina Galletti1, Mattia Mandolfino1, Flavia Di Bari1, Marco Centanni2,4 and Salvatore Benvenga1,5,6

1Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy. 2Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Latina, Italy. 3Department of Pediatrics and Child Neuropsychiatry, Sapienza University of Rome, Rome, Italy. 4Endocrinology Unit, AUSL Latina, Latina, Italy. 5Master Program on Childhood, Adolescent and Women’s Endocrine Health, University of Messina, Messina, Italy. 6Interdepartmental Program of Molecular & Clinical Endocrinology, and Women’s Endocrine Health, University Hospital Policlinico Universitario G. Martino, Messina, Italy

Polyglandular autoimmune syndrome (PAS) type 3 consists of autoimmune thyroid disease (AITD) coexisting with ≥1 non-thyroidal autoimmune disease (NTAID) other than Addison’s disease and hypoparathyroidism. We evaluated the prevalence and repertoire of thyroid hormones antibodies (THAb) in PAS-3 patients. Using a radioimmunoprecipitation technique, we measured THAb (T3IgM, T3IgG, T4IgM, and T4IgG) in 107 PAS-3 patients and 88 controls (patients with AITD without any NTAID). Based on the selective coexistence of AITD with one NTAID (chronic autoimmune gastritis, non-segmental vitiligo or celiac disease), patients were divided into group 1 (chronic autoimmune gastritis positive, n = 64), group 2 (non-segmental vitiligo positive, n = 24), and group 3 (celiac disease positive, n = 15). At least one of the four THAb was detected in 45 PAS-3 patients (42.1%) and 28 controls (31.8%, P = 0.14), with similar rates in the three PAS-3 groups. The rates of T3Ab, T4Ab, and T3 + T4Ab were similar in groups 1 and 2, while in group 3, T3Ab was undetected (P = 0.02). In PAS-3 patients, the rate of levothyroxine treatment was greater in THAb-positive patients compared to THAb-negative patients (42.1% and 28 controls (31.8%, P = 0.14), with similar rates in the three PAS-3 groups. The rates of T3Ab, T4Ab, and T3 + T4Ab were similar in groups 1 and 2, while in group 3, T3Ab was undetected (P = 0.02). In PAS-3 patients, the rate of levothyroxine treatment was greater in THAb-positive patients compared to THAb-negative patients (76.7 vs. 56.1%, P = 0.03, RR = 1.4, 95% CI 1.03–1.81). Not unexpectedly, levothyroxine daily dose was significantly higher in group 1 and group 3, namely in patients with gastrointestinal disorders, compared to group 2 (1.9 ± 0.4 and 1.8 ± 0.3 vs. 1.5 ± 0.2 μg/kg body weight, P = 0.0005 and P = 0.004). Almost half of PAS-3 patients have THAb, whose repertoire is similar if chronic autoimmune gastritis or celiac disease is present. A prospective study would confirm whether THAb positivity predicts greater likelihood of requiring levothyroxine treatment.

Keywords: thyroid hormone antibodies, chronic autoimmune thyroiditis, chronic atrophic gastritis, non-segmental vitiligo, celiac disease

Abbreviations: AITD, autoimmune thyroid disease; L-T4, levothyroxine; NTAID, non-thyroidal autoimmune disease; PAS, polyglandular autoimmune syndrome; THAb, thyroid hormones antibodies.
INTRODUCTION

Polyglandular autoimmune syndromes (PAS) are defined by the coexistence of different clusters of autoimmune diseases (1). Neufeld and Blizzard (2) originally defined PAS-3 as the association between one autoimmune thyroid disease (AITD) and one or more non-thyroidal autoimmune diseases (NTAID) other than Addison’s disease and hypoparathyroidism, since these two last diseases identify PAS-1 and PAS-2, respectively (1, 3). NTAID included in PAS-3 were type 1 diabetes mellitus (PAS type 3A); autoimmune chronic atrophic gastritis and pernicious anemia (type 3B); and vitiligo, alopecia, and myasthenia gravis (type 3C) (2). Subsequently, Betterle defined PAS-3 based on the different organ-specific and non-organ-specific NTAID that are associated with AITD (Hashimoto’s thyroiditis, idiopathic myxedema, symptomless autoimmune thyroiditis, Graves’ disease, and thyroid-associated ophthalmopathy) (4, 5). PAS-3A includes autoimmune endocrine diseases (type 1 diabetes mellitus, lymphocytic hypophysitis, premature ovarian failure, and Hirata’s disease); PAS-3B includes gastrointestinal autoimmune diseases (chronic atrophic gastritis, pernicious anemia, celiac disease, and chronic inflammatory bowel diseases) and hepatic autoimmune diseases (autoimmune hepatitis, primary biliary cirrhosis); PAS-3C comprises skin autoimmune diseases (vitiligo, alopecia, and urticaria), and nervous system autoimmune diseases (myasthenia gravis, multiple sclerosis, and stiff-man syndrome); PAS-3D includes collagen diseases (lupus erythematosus and its variants, rheumatoid arthritis, seronegative arthritis, systemic sclerosis, and mixed connective tissue disease), Sjogren syndrome, vasculitis, and hematologic autoimmune diseases (Werlhof’s syndrome and antiphospholipid syndrome) (4, 5).

The most common AITD is Hashimoto’s thyroiditis, also known as chronic lymphocytic thyroiditis. Like other autoimmune endocrine diseases, the prevalence of Hashimoto’s thyroiditis has shown a remarkable upward trend over the last decades (6, 7). The hallmarks of Hashimoto’s thyroiditis are the hypoechoic ultrasound pattern of thyroid and the high rate of positivity of thyroid autoantibodies (namely, antibodies directed against thyroglobulin and thyroperoxidase) (6). Interestingly, a decline in prevalence and serum levels of thyroid autoantibodies was noticed over the last decades in patients with Hashimoto’s thyroiditis, together with a specular increase in the prevalence of thyroid hormones autoantibodies (THAb) (6). Indeed, in those patients, the rate of THAb positivity increased by eightfold (from 5 to 40%) over the period 1975–2005 (6, 8). THAb are found in patients with Graves’ disease in around one-third of cases (8, 9). Also, the real prevalence of THAb may be underestimated because they are not routinely assayed and can appear transiently in serum (8, 10). THAb, which can be found in approximately 1% of the general population, are directed against T3, T4, or both, and may belong to IgM, IgG, or both classes (8, 11). Our group has shown that at least one THAb can be found in sera of patients with NTIAID even more frequently compared to AITD, regardless of thyroglobulin and/or thyroperoxidase antibodies status. For instance, in primary Sjogren syndrome or rheumatoid arthritis, the rate of THAb positivity was 55 or 40%, respectively, and has increased steadily over the last years (8, 9). Recently, the highest rates of THAb positivity were found in patients with type 1 diabetes mellitus or vitiligo, since approximately all of them carried at least one THAb (12–14).

Because never studied before, we evaluated the prevalence and repertoire of THAb in PAS-3 patients.

SUBJECTS AND METHODS

This study complies with the Declaration of Helsinki. Informed consent has been obtained from each patient after full explanation of the purpose and nature of all procedures used. Since this was not an interventional study, we did not need any approval by the Internal Review Board.

Our cohort consists of 107 consecutive PAS-3 patients (90 females, 17 males, F:M ratio = 5.3:1), aged 15–82 years at first observation and associated blood sampling. All patients had one AITD [Hashimoto’s thyroiditis (n = 103), Graves’ disease (n = 4)] associated with at least one NTAID. On the basis of the three most prevalent NTAID (chronic atrophic gastritis, non-segmental vitiligo, and celiac disease), we divided the 107 patients into three mutually exclusive groups. In group 1 patients (n = 66; 61.7%), HT coexisted with chronic atrophic (autoimmune) gastritis alone (n = 42) or chronic atrophic gastritis plus at least another NTAID (n = 24) (Table 1). In group 2 patients (n = 26; 24.3%), HT coexisted with non-segmental vitiligo alone (n = 24) or non-segmental vitiligo plus at least another NTAID (n = 2) (Table 1). Finally, in group 3 patients (n = 15; 14.0%), HT coexisted with only celiac disease and no patient presented with celiac disease plus another NTAID (Table 1).

The control group was previously studied to also serve as a control group in another setting (9). It consisted of a previously cohort of 88 Hashimoto’s thyroiditis patients (77 women, 11 men, F:M ratio = 7:1; age 42 ± 9 years) who had never been treated with levothyroxine (L-T4) and, importantly, had no NTAID.

Diagnosis of Autoimmune Diseases

Hashimoto’s thyroiditis was defined by hypoechoic and inhomogeneous echopattern with or without positivity of either or both thyroid autoantibodies (thyroglobulin antibodies and thyroperoxidase antibodies) (6, 15). Diagnosis of chronic atrophic gastritis was based on parietal cell antibodies positivity and histological confirmation (i.e., focal or complete loss of oxyntic glands and/or replacement by metaplastic pyloric or intestinal glands) (16). According to the Vitiligo European Task Force definition (17), non-segmental vitiligo was defined by the presence of white patches of skin, generally symmetrical and growing in size. Celiac disease was supported by positivity of serum transglutaminase antibodies (IgG and IgA) and/or endomysial antibodies (IgG and IgA). Celiac disease was histologically confirmed after duodenum and jejenum biopsies showing various degrees of intestinal atrophy and crypt hyperplasia according to the Marsh classification, as modified by Oberhuber (18).
Thyroid Hormone Autoantibodies (THAb) Assay

We assayed serum THAb (T3IgM, T3IgG, T4IgM, and T4IgG) by a previously described radioimmunoprecipitation technique (10, 12, 19). Five hundred microliters of serum, which had been stored at -20°C, were incubated with 0.5 µCi [125I]T3 or [125I]T4 (Johnson and Johnson, Milan, Italy) for 60 min at 23°C. Twenty microliters of this mixture were incubated with 150 µL solution containing antihuman IgM or antihuman IgG serum (Sigma-Aldrich, Milan, Italy) at a concentration of 0.5% for 24 h at 4°C. Both antihuman IgM and antihuman IgG serum had been stored at –20°C, were incubated with 0.5 Ci [125I]T3 or [125I]T4 (Johnson and Johnson, Milan, Italy) for 60 min at 23°C. The mixture obtained was then centrifuged at 2,000 x g for 20 min, and the supernatant was aspirated. T3Ab and T4Ab were assayed in two different runs. We also assayed THAb in negative and positive controls, namely sera negative for all four types of THAb or sera positive for one type of THAb (T3IgM, T3IgG, T4IgM, or T4 IgG). Each serum was analyzed in duplicate for each THAb. THAb positivity was defined by a proportion of the [125I]T3 or [125I]T4 immunoprecipitated by the corresponding antisera >3.9%, >3.6%, >3.4%, or >3.9% for T3IgM, T3IgG, T4IgM, or T4IgG, respectively (10, 12, 19). In case of borderline values, assay was repeated.

Statistics

Data are reported as mean ± SD. Comparisons between proportions were handled with the chi-squared test or the Fisher’s exact test as appropriate. Comparisons between continuous variables were handled with the Mann–Whitney test or the Kruskal–Wallis test as appropriate. Level of significance was set at 0.05.

RESULTS

Demographics

The mean age at first observation in the 107 PAS-3 patients was 50.5 years (range 15–82 years). Group 1 patients were significantly older compared with group 2 (55.4 ± 13.6 vs. 45.5 ± 14.1 years, P = 0.004) and group 3 (55.3 ± 13.8 vs. 37.4 ± 12.2 years, P < 0.0001) patients, while group 3 patients were younger, although not significantly, compared to group 2 patients (P = 0.06) (Table 1). Not unexpectedly patients with chronic autoimmune gastritis were the oldest, as this autoimmune disease peaks some decades later (16) in contrast with non-segmental vitiligo (17) and celiac disease (20).

The female-to-male ratio (F:M) was significantly greater in group 1 than in group 2 (61.5 or 12.2:1 vs. 16:10 or 1.6:1, P = 0.0008).

Excluding the four patients with Graves’ disease, at first observation, 67/107 HT patients (62.6%) were under replacement L-T4 therapy, with similar intragroup rates (group 1, 45/66, 68.2%; group 2, 16/26, 61.5%; group 3, 6/15, 40%).

Prevalence and Repertoire of THAb

All data are summarized in Table 2. Overall, THAb were detected in 45/107 patients (42.1%), without significant differences between groups (43.9, 42.3, and 33.3% in groups 1, 2 and 3, respectively).

Single THAb were the most prevalent (36.4%), again with no intergroup differences (33.3–37.9%), whereas quadruple THAb were always absent. Within the single THAb category, the four types of THAb were distributed similarly in groups 1 and 2 (df = 3, χ² = 2.2, P = 0.53), but dissimilarly between groups 1 and 3 (df = 3, χ² = 14.4, P = 0.002) or between groups 2 and 3 (df = 3, χ² = 10.7, P = 0.01). Because of very low or absent types of THAb in the double, triple, or quadruple categories, no intergroup statistics was possible (Table 2).

Concerning categorization based on the thyroid hormones bound (i.e., T3 only, T4 only, and T3 plus T4), groups 1 and 2 did not differ. In contrast, because of the selective binding of T4 by THAb in group 3 patients, this group differed from both group 1 (df = 2, χ² = 10.8, P = 0.005) and group 2 (df = 2, χ² = 7.3,
TABLE 2 | Prevalence and repertoire of THAb.

| THAb            | AITD + CAG n = 66 | AITD + NSV n = 26 | AITD + CD n = 15 | PAS-3 n = 107 | HT+ n = 88 Controls |
|-----------------|-------------------|-------------------|------------------|---------------|-------------------|
| T3Ab            |                   |                   |                  |               |                   |
| Single THAb     |                   |                   |                  |               |                   |
| IgM             | 37 (56.1%)        | 15 (57.7%)        | 0 (0%)           | 62 (57.9%)    | 60 (68.2%)        |
| IgG             | 29 (43.9%)        | 11 (42.3%)        | 5 (33.3%)        | 45 (42.1%)    | 28 (31.8%)        |
| At least one of the four +ve |                   |                   |                  |               |                   |
| +               | 25 (37.9%)        | 9 (34.6%)         | 5 (33.3%)        | 39 (36.6%)    | 19 (21.6%)        |
| No              | 13 (19.7%)        | 3 (11.6%)         | 0 (0%)           | 16 (14.9%)    | 2 (2.3%)          |
| No              | 5 (7.6%)          | 3 (11.6%)         | 0 (0%)           | 8 (7.5%)      | 6 (6.8%)          |
| No              | 2 (3.0%)          | 0 (0%)            | 4 (26.7%)        | 6 (5.6%)      | 8 (9.1%)          |
| No              | 7 (10.2%)         | 3 (1.8%)          | 0 (0%)           | 1 (1.1%)      | 0 (0%)            |

Based on hormone bound

| T3 only (IgM, IgG, or both) | 20 (30.3%) | 7 (26.9%) | 0 | 27 (25.2%) | 13 (14.8%) |
| T4 only (IgM, IgG, or both) | 7 (10.6%)  | 3 (11.5%) | 5 (33.3%) | 15 (14.0%) | 12 (13.6%) |
| T3 and T4 (IgM, IgG, or both) | 2 (3.0%) | 1 (3.8%) | 0 | 3 (2.8%) | 3 (3.4%) |
| All absent           | 37 (56.1%) | 15 (57.7%) | 10 (66.7%) | 62 (57.9%) | 60 (68.2%) |

Based on Ig class

| IgM only (T3, T4, or T3 + T4) | 15 (22.7%) | 3 (11.5%) | 4 (26.7%) | 22 (20.6%) | 11 (12.5%) |
| IgG only (T3, T4, or T3 + T4) | 10 (15.1%) | 6 (23.1%) | 1 (6.7%) | 17 (15.9%) | 9 (10.2%) |
| IgM and IgG (T3, T4, or T3 + T4) | 4 (6.1%) | 2 (7.7%) | 0 | 6 (5.6%) | 8 (9.1%) |
| All absent           | 37 (56.1%) | 15 (57.7%) | 10 (66.7%) | 62 (57.9%) | 60 (68.2%) |

Based on the thyroid hormones bound, in PAS-3 patients, the most prevalent THAb were against T3 (25.2%) compared to those against T4 (14%) or both T3 and T4 (2.8%). In contrast, the corresponding rates in controls were 14.8, 13.6, and 3.4% (P = 0.51) (Table 2). PAS-3 patients and controls did not differ either in the repertoire of THAb based on immunoglobulin classes (P = 0.27) (Table 2).

Association of THAb with Number of NTAID

The average number of NTAID was the highest in group 1 patients, the lowest in group 3 patients, and intermediate in group 2 patients (1.4 vs. 1.0 vs. 1.1, P = 0.0009). Indeed, around one-third (36.4%) of group 1 patients had at least two NTAID, in contrast with 2/26 (7.7%) patients in group 2 and none in group 3 (36.4 vs. 7.7% vs. 0, df = 2, χ² = 13.9, P = 0.0009).

Association of THAb with Replacement L-T4 Therapy in PAS-3 Patients

Seventy patients (65.4%) were on L-T4 replacement therapy at the time of blood sampling. THAb-positive PAS-3 patients

For abbreviations, see Table 1 footnote.

*At time of blood sampling, there was no non-thyroid autoimmune disease associated with HT.

P = 0.03). In regard to categorization based on the immunoglobulin classes of THAb (i.e., IgM only, IgG only, and IgM plus IgG), group 3 did not differ from the other two groups (χ² = 1.6, P = 0.45 vs. group 1; χ² = 4.0, P = 0.13 vs. group 2), with groups 1 and 2 not differing either (χ² = 2.0, P = 0.37) (Table 2).

Six of the 13 group 1 patients with pernicious anemia carried one THAb (three patients carried T4IgG, two patients T3IgM, and one patient T4IgM). Only one patient of the three with rheumatoid arthritis or Sjogren syndrome was THAb positive (T3IgM).
Another explanation is that material leaking from the inflamed can be assayed by conventional methods are undetectable (thyroiditis are characterized by serum reactivity against either present in NTAID. Indeed, the early stages of lymphocytic very initial autoimmune inflammation of the thyroid is already explanation for the detection of THAb in NTAID eliciting THAb synthesis with high frequency (the said hormonogenic epitopes (aggravation of the autoimmune inflammation (course of Hashimotos' thyroiditis, for instance during phases of of such thyroglobulin molecules may occur naturally in the time leakage of iodinated and heterologous moieties (the FNAC-elicited release of iodinated and heterologous moieties of thyroglobulin that were absent prior to FNAC. Leakage of such thyroglobulin molecules may occur naturally in the time course of Hashimotos' thyroiditis, for instance during phases of aggravation of the autoimmune inflammation (8). Inflammatory cytokines may disclose hidden thyroglobulin epitopes, which are capable to elicit autodestructive production by B-lymphocytes that infiltrate the thyroid (8). Post-translational modifications of thyroglobulin may increase its antigenicity by better exposing the said hormonogenic epitopes (21). For instance, in patients with type 1 diabetes mellitus, glycosylated thyroglobulin might elicit THAb synthesis with high frequency (12). One possible explanation for the detection of THAb in NTAID per se is that a very initial autoimmune inflammation of the thyroid is already present in NTAID. Indeed, the early stages of lymphocytic thyroiditis are characterized by serum reactivity against either thyroid hormone, even though thyroglobulin antibodies that can be assayed by conventional methods are undetectable (22). Another explanation is that material leaking from the inflamed peripheral tissues of NTAID patients (e.g., joints, stomach, intestine, and skin) and, regardless of sharing molecular mimicry with thyroglobulin, binds thyroid hormones, thus forming novel iodinated autoantigens (8).

Concerning the THAb repertoire, double or triple THAb positivity was much less common compared to single positivity. Particularly, of the 52 THAb detected in the 45 THAb-positive PAS-3 patients, three-fourth (39/52, 75%) were directed against either T3 or T4. Concerning hormone specificity of THAb, while in groups 1 and 2, T3Ab outnumbered T4Ab, and in group 3, the distribution was inverted. This difference resembled that found in patients with type 1 diabetes mellitus, in which the rate of T3Ab or T4Ab positivity was 38.5% (20/52) or 27.1% (12/52) (12). Interestingly, no patient of this cohort had type 1 diabetes mellitus. In patients with only Hashimoto's thyroiditis, T3Ab and T4Ab were equally distributed (Table 2). Classes of THAb varied remarkably among groups, with a preponderance of T3IgM or T4IgM in group 1 or group 3, and similar rates of T3IgM, T3IgG, and T4IgG in group 2. Thus, overall, primary immune response (i.e., IgM) prevailed over a stable secondary immune response (i.e., IgG). Concerning additional NTAID, they were more common in group 1. This was not unexpected, since those patients were older than group 2 and group 3 patients (see above). The most common additional NTAID was pernicious anemia, which was found in 1/4 patients with chronic atrophic gastritis. Pernicious anemia results from vitamin B₁₂ deficiency and may occur in patients with advanced chronic inflammation of the gastric corpus. In up to 80% of patients with pernicious anemia, autoantibodies against intrinsic factor, which impair vitamin B₁₂ absorption, are found (16, 23).

THAb positivity was associated with a greater risk of hypothyroidism (RR = 1.4, 95% CI 1.03–1.81) regardless of the hormone bound or the class of immunoglobulin. Indeed, more than 3/4 THAb-positive PAS-3 patients had required L-T4 as thyroid replacement, in contrast with around half of THAb-negative PAS-3 patients. Not unexpectedly patients with the greatest requirements of L-T4 were those with gastric autoimmune gastritis or celiac disease, two disorders that are associated with impaired intestinal absorption of L-T4 (24–27). For instance, patients with chronic atrophic gastritis need a 27% increase in L-T4 dose in order to achieve target serum TSH levels (24, 28). Furthermore, atrophic gastritis can be associated with a long-standing Helicobacter pylori infection in up to 30% of cases (16, 29). Compared to H. pylori-negative patients, those with a concurrent H. pylori infection need a greater increase in L-T4 dose (+34 vs. +24%) (24).

One limitation of this otherwise novel study is its cross-sectional design. Therefore, we could not evaluate (i) the occurrence of other NTAID over time based on THAb status, (ii) the switch of immune response from IgM to IgG, and (iii) changes of the rate of hypothyroidism over time based on THAb status. In conclusion, almost half of PAS-3 patients have THAb, whose repertoire is similar in the group with autoimmune gastritis and the group with celiac disease. A prospective study would confirm whether THAb positivity predicts a greater likelihood of requiring L-T4 treatment over the years.
ETHICS STATEMENT

This study complies with the Declaration of Helsinki. Informed consent has been obtained from each patient after full explanation of the purpose and nature of all procedures used.

REFERENCES

1. Eisenbarth GS, Gottlieb PA. Autoimmune polyendocrine syndrome. N Engl J Med (2012) 350:2068–79. doi:10.1056/NEJMra030158
2. Neufeld M, Blizard RM. Polyglandular autoimmune diseases. In: Pinchera A, Doniach D, Fenić GF, Baschieri L, editors. Symposium on Autoimmune Aspects of Endocrine Disorders. New York: Academic Press (1980). p. 357–65.
3. Kahaly GJ. Polyglandular autoimmune syndromes. Eur J Endocrinol (2009) 161:11–20. doi:10.1530/EJE-09-0044
4. Betterle C, Dal Pra C, Mantero F, Zanchetta R. Autoimmune adrenal insufficiency and adrenal polyendocrine syndromes: autoantibodies, autoantigens, and their applicability in diagnosis and disease prediction. Endocr Rev (2002) 23:327–64. doi:10.1210/edrv.23.3.0466
5. Amero P, Tracanna M, De Remigis P, Betterle C, Vianale L, Marra ME, et al. Vitiligo associated with other autoimmune diseases: polyglandular autoimmune syndrome types 3B+C and 4. Clin Exp Dermatol (2006) 31:746–9. doi:10.1111/j.1365-2230.2006.02171.x
6. Benvenenga S, Tramarchi F. Changed presentation of Hashimoto's thyroiditis in North-Eastern Sicily and Calabria (Southern Italy) based on a 31-year experience. Thyroid (2008) 18:429–41. doi:10.1089/thy.2007.0224
7. Benvenenga S, Guarneri F. Molecular mimicry and autoimmune thyroid disease. Rev Endocr Metab Disord (2016) 17:485–98. doi:10.1007/s11154-016-9363-2
8. Benvenenga S, Tramarchi F. Increasing frequency and clinical significance of thyroid hormone autoantibodies. Curr Opin Endocrinol Diabetes (2004) 11:209–13. doi:10.1097.01.med.0000137579.57791.f8
9. Mondello P, Mian M, Pitini V, Cuzzocrea S, Sindoni A, Galletti M, et al. Thyroid hormone autoantibodies: are they a better marker to detect early thyroid damage in patients with hematologic cancers receiving tyrosine kinase inhibitor or immunoregulatory drug treatments? Curr Oncol (2016) 23:e165–70. doi:10.3745/co.23.3026
10. Benvenenga S, Bartolone L, Squadrito S, Tramarchi F. Thyroid hormone autoantibodies elicited by diagnostic fine needle biopsy. J Clin Endocrinol Metab (1997) 82:4217–23. doi:10.1210/jc.82.12.4217
11. Benvenenga S, Burek CL, Talor M, Rose NR, Tramarchi F. Heterogeneity of the thyroglobulin epitopes associated with circulating thyroid hormone autoantibodies in hashimoto's thyroiditis and non-autoimmune thyroid diseases. J Endocrinol Invest (2002) 25:977–82. doi:10.1007/BF03344071
12. Benvenenga S, Pintaudi B, Vita R, Di Vieste G, Di Benedetto A. Serum thyroid hormone autoantibodies in type 1 diabetes mellitus. J Clin Endocrinol Metab (2015) 100:1870–8. doi:10.1210/jc.2014-3950
13. Colucci R, Lotti F, Arunachalam M, Lotti T, Benvenenga S, et al. High prevalence of circulating autoantibodies against thyroid hormones in vitiligo and correlation with clinical and historical parameters of patients. Br J Dermatol (2014) 171:786–98. doi:10.1111/bjd.13286
14. Colucci R, Lotti F, Arunachalam M, Lotti T, Dragoni F, Benvenenga S, et al. Correlation of serum thyroid hormone autoantibodies with self-reported exposure to thyroid disruptors in a group of nonsegmental vitiligo patients. Arch Environ Contam Toxicol (2015) 69:181–90. doi:10.1007/s00244-015-0138-7
15. Weetman AP. Chronic autoimmune thyroiditis. In: Braverman LE, Utiger RD, editors. Werner and Ingbar's The Thyroid, 9th ed. Philadelphia: Lippincott Williams & Wilkins (2005). p. 701–13.
16. Neumann WL, Coss E, Rugge M, Genta RM. Autoimmune atrophic gastritis – pathogenesis, pathology and management. Nat Rev Gastroenterol Hepatol (2013) 10:529–41. doi:10.1038/nrgastro.2013.101

AUTHOR CONTRIBUTIONS

SB conceived the study. MG and MM performed the THAb assays. RV, MGS, CV, MS, FB, MC, and SB analyzed the data. RV, MGS, CV, MC, and SB drafted the manuscript. All the authors contributed to the final revision of the manuscript.

17. Taieb A, Picardo M, VETF Members. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res (2007) 20:27–35. doi:10.1111/j.1600-0769.2006.00355.x
18. Oberhuber G. Histopathology of celiac disease. Biomed Pharmacother (2000) 54:368–72. doi:10.1016/S0753-3322(01)80003-2
19. Tramarchi F, Benvenenga S, Costante G, Barbera C, Melluso R, Maroccoci C, et al. Identification and characterization of circulating thyroid hormone autoantibodies in thyroid diseases, in autoimmune non thyroid illnesses and in lymphoepithelial system disorders. J Endocrinol Invest (1983) 6:203–9. doi:10.1007/BF03350609
20. West J, Fleming KM, Tata LJ, Card TR, Crooks CJ. Incidence and prevalence of celiac disease and dermatitis herpetiformis in the UK over two decades: population-based study. Am J Gastroenterol (2014) 109:757–68. doi:10.1038/ajg.2014.55
21. Dunn JT, Dunn AD. Thyroglobulin: chemistry, biosynthesis and proteolysis. In: Braverman LE, Utiger RD, editors. Werner and Ingbar's The Thyroid, 7th ed. Philadelphia: Lippincott-Raven (1996). 90 p.
22. Kuppers RC, Bresler HS, Burek CL, Gleason SL, Rose NR. Immunodominant determinants of thyroglobulin-associated with autoimmune thyroiditis. In: Bona CA, Kaushick AK, editors. Molecular Immunobiology of Self-Reactivity. New York: Marcel Dekker (1992). p. 247–60.
23. Sibilla R, Santaguida MG, Virili C, Gargano L, Nardo S, Della Guardia M, et al. Chronic unexplained anaemia in isolated autoimmune thyroid disease or associated with autoimmune related disorders. Clin Endocrinol (Oxf) (2008) 68:640–5. doi:10.1111/j.1365-2265.2007.03091.x
24. Centanni M, Gargano L, Canettieri G, Viceconti N, Franchi A, Delle Fave G, et al. Thyroxine goiter, Helicobacter pylori infection, and chronic gastritis. N Engl J Med (2006) 354:1787–95. doi:10.1056/NEJMoa049303
25. Virili C, Bassotti G, Santaguida MG, Iurio R, Del Duca SC, Mercuri V, et al. Atypical celiac disease as cause of increased need for thyroxine: a systematic study. J Clin Endocrinol Metab (2012) 97:E419–22. doi:10.1210/jc.2011-1851
26. Benvenenga S. When thyroid hormone replacement is ineffective? Curr Opin Endocrinol DiabetesObes(2013)20:467–77.doi:10.1097/MED.0000000000000003
27. Liwanpo L, Hershman J.M. Conditions and drugs interfering with thyroxine absorption. Best Pract Res Clin Endocrinol Metab (2009) 23:781–92. doi:10.1016/j.beem.2009.06.006
28. Checchi S, Montanaro A, Pasqui L, Ciucci V, De Palo V, Chiappetta MC, et al. l'-Thyroxine requirement in patients with autoimmune hypothyroidism and parietal cell antibodies. J Clin Endocrinol Metab (2008) 93:465–9. doi:10.1210/jc.2007-1544
29. Lahner E, Virili C, Santaguida MG, Annibale B, Centanni M. Helicobacter pylori infection and drugs malabsorption. World J Gastroenterol (2014) 20:10331–7. doi:10.3748/wjg.v20.i30.10331

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.